NO964199L - Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon - Google Patents

Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon

Info

Publication number
NO964199L
NO964199L NO964199A NO964199A NO964199L NO 964199 L NO964199 L NO 964199L NO 964199 A NO964199 A NO 964199A NO 964199 A NO964199 A NO 964199A NO 964199 L NO964199 L NO 964199L
Authority
NO
Norway
Prior art keywords
type
interferon
treatment
oral tolerance
autoimmune disease
Prior art date
Application number
NO964199A
Other languages
English (en)
Other versions
NO964199D0 (no
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964199D0 publication Critical patent/NO964199D0/no
Publication of NO964199L publication Critical patent/NO964199L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)

Abstract

Fremgangsmåte for behandling av autoimmune sykdommer så som multippel sklerose ved oral administrering av et tilstedeværende antigen så som myelinbasisk protein eller proteolipid protein sammen med et polypeptid som har type I interferon aktivitet på en slik måte at det induserer oral toleranse til det tilstedeværende antigenet som resulterer i suppresjon av den autoimmune responsen.
NO964199A 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon NO964199L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
NO964199D0 NO964199D0 (no) 1996-10-03
NO964199L true NO964199L (no) 1996-10-03

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964199A NO964199L (no) 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (no)
JP (1) JPH09511745A (no)
AU (1) AU686797B2 (no)
BR (1) BR9507451A (no)
CA (1) CA2185353A1 (no)
HU (1) HUT74900A (no)
IL (1) IL113303A0 (no)
NO (1) NO964199L (no)
WO (1) WO1995027499A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
KR101042660B1 (ko) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU6481301A (en) 2000-05-24 2001-12-03 Us Health Methods for preventing strokes by inducing tolerance to e-selectin
WO2004058295A1 (ja) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. 類天疱瘡治療剤
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
AU2010234743A1 (en) * 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
HU220357B (hu) * 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával

Also Published As

Publication number Publication date
HU9602750D0 (en) 1996-11-28
EP0752880A1 (en) 1997-01-15
HUT74900A (en) 1997-02-28
NO964199D0 (no) 1996-10-03
AU2277695A (en) 1995-10-30
WO1995027499A1 (en) 1995-10-19
JPH09511745A (ja) 1997-11-25
CA2185353A1 (en) 1995-10-19
EP0752880A4 (en) 2000-08-09
AU686797B2 (en) 1998-02-12
IL113303A0 (en) 1995-07-31
BR9507451A (pt) 1997-08-05

Similar Documents

Publication Publication Date Title
ATE228373T1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
ATE219373T1 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69820053D1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
ZA947783B (en) Method of treating depressed reticuloendothelial system function
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
DK0752884T3 (da) Fremgangsmåde til behandling af auto-immune sygdomme ved anvendelse af type 1 interferoner
NO982463L (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
EP0642333A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH IMMUNOLOGICAL DYSFUNCTION.
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології
RU97119885A (ru) Способ выведения больных из посттравматической комы и апаллического состояния

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application